{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:56:00Z","timestamp":1792608960246,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,8]]},"abstract":"\n The mechanisms by which SGLT\u20102 inhibitors lower albuminuria are incompletely understood. We assessed in a\n post\u2010hoc<\/jats:italic>\n analysis of a cross\u2010over trial the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM\u20101, NGAL and LFABP) and inflammatory markers (urinary MCP\u20101 and IL\u20106) to provide more insight into kidney protective effects. Dapagliflozin decreased albuminuria by 43.9% (95% CI, 30.3%\u201054.8%) and eGFR by 5.1 (2.0\u20108.1) mL\/min\/1.73m\n 2<\/jats:sup>\n compared to placebo. Dapagliflozin did not change glomerular charge or size selectivity index compared to placebo. Dapagliflozin decreased urinary KIM\u20101 excretion by 22.6% (0.3%\u201039.8%;\n P<\/jats:italic>\n \u2009=\u2009.05) and IL\u20106 excretion by 23.5% (1.4%\u201040.6%;\n P<\/jats:italic>\n \u2009=\u2009.04) compared to placebo, whereas no changes in NGAL, LFABP and MCP\u20101 were observed. During dapagliflozin treatment, changes in albuminuria correlated with changes in eGFR (r\u2009=\u20090.36;\n P<\/jats:italic>\n \u2009=\u2009.05) and KIM\u20101 (r\u2009=\u20090.39;\n P<\/jats:italic>\n \u2009=\u2009.05). In conclusion, the albuminuria\u2010lowering effect of 6 weeks of dapagliflozin therapy may be the result of decreased intraglomerular pressure or reduced tubular cell injury.\n <\/jats:p>","DOI":"10.1111\/dom.13301","type":"journal-article","created":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T19:52:43Z","timestamp":1521921163000},"page":"1988-1993","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":239,"title":["Effects of the SGLT\u20102 inhibitor dapagliflozin on glomerular and tubular injury markers"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-7240","authenticated-orcid":false,"given":"Claire C. J.","family":"Dekkers","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Petrykiv","sequence":"additional","affiliation":[{"name":"Department of Nephrology University of Groningen, University Medical Center Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozewijn D.","family":"Laverman","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ziekenhuisgroep Twente, Almelo and Hengelo The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.","family":"Cherney","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology Toronto General Hospital, University of Toronto Toronto Canada"},{"name":"Department of Physiology and Banting and Best Diabetes Centre University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016030278"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013090950"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30237-6"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2760w"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2012.07.008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12936"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016101127"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050093"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30182-1"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00331.2013"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005070757"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00689.2014"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007091048"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050556"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00311.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.05.014"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054442"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006040377"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:57:46Z","timestamp":1761886666000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/dom.13301"],"URL":"https:\/\/doi.org\/10.1111\/dom.13301","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"assertion":[{"value":"2018-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}